Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026
← Back to Research Index
Compare Evaluate Matrix Half-Life
Dossier · № 50 of 110 Updated Nov 17, 2026

ARA-290

Cibinetide · pHBSP

PHASE 2 · EPO-DERIVED PEPTIDE; INNATE REPAIR RECEPTOR (IRR) AGONIST

▓ 68 indexed citations across PubMed (51), ClinicalTrials.gov (4), EuropePMC (13).

Citation breakdown by evidence tier

← weaker evidence  ·  stronger evidence →

68 citations across 6 tiers

Tap any tier to jump to that section of the bibliography.

Mechanism of action

Activates IRR heterocomplex (EpoR/βcR); tissue protection without hematopoietic effect

Researched effects

Small fiber neuropathy pain reduction; tissue protection; sarcoidosis neuropathy benefit

Reported efficacy (trial readout)

  • Neuropathy Pain Reduction 11.5 SFNSL score change

    ARA-290 in SFN pilot RCT (4wk)

    Medium confidence

Trial-efficacy data current as of November 16, 2026.

Live evidence

Live signals refreshed daily. Current as of November 19, 2026.

Dosing reported in literature

2-4 mg SC daily for 28 days (trial protocol)

Known concerns

Injection site reactions; Phase 2/3 data limited

Top-ranked picks

10 pre-curated authoritative sources, ranked by journal tier and study weight.

  1. The effects of pharmacological interventions on quality of life and fatigue in sarcoidosis: a systematic review.

    2020 — SYSTEMATIC REVIEWS · AUTHORITY 84.0

  2. Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain.

    Investigative ophthalmology & visual science · 2017 — RANDOMISED CONTROLLED TRIALS · AUTHORITY 73.7

  3. ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density.

    Molecular medicine (Cambridge, Mass.) · 2013 — RANDOMISED CONTROLLED TRIALS · AUTHORITY 73.3

  4. Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study.

    Molecular medicine (Cambridge, Mass.) · 2012 — RANDOMISED CONTROLLED TRIALS · AUTHORITY 73.2

  5. Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis

    2014 — TRIAL REGISTRATIONS (CLINICALTRIALS.GOV) · AUTHORITY 72.4

  6. Cognitive and Neural Effects of ARA290

    2012 — TRIAL REGISTRATIONS (CLINICALTRIALS.GOV) · AUTHORITY 72.2

  7. The Use of ARA290 for the Treatment of Diabetic Macular Oedema

    2016 — TRIAL REGISTRATIONS (CLINICALTRIALS.GOV) · AUTHORITY 68.6

  8. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes.

    Molecular medicine (Cambridge, Mass.) · 2015 — CLINICAL TRIALS · AUTHORITY 68.5

  9. ARA290 in T2D (Effects of ARA 290, an Erythropoietin Analogue) in Prediabetes and Type 2 Diabetes)

    2013 — TRIAL REGISTRATIONS (CLINICALTRIALS.GOV) · AUTHORITY 67.3

  10. The protective effect of erythropoietin and its novel derived peptides in peripheral nerve injury.

    International immunopharmacology · 2024 — REVIEWS · AUTHORITY 54.4

Full citation library

Year distribution

Systematic Reviews

1
  1. 1.

    Vis R, van de Garde EMW, Grutters JC, Korenromp IHE. · 2020 · PMID 31996355

    <h4>Aims</h4>Many sarcoidosis patients experience a reduction in health-related quality of life (HRQoL) and a majority of patients report fatigue. Historically, drug trials in sarcoidosis have focused on changes in chest radiographs, lung function parameters and biomarkers, while HRQoL and fatigue have not been the main outcomes examined. We performed a systematic review of the literature to evaluate the existing evidence on the effects of pharmacological interventions on HRQoL and fatigue outco…

Randomised Controlled Trials

3
  1. 2.

    Culver DA, Dahan A, Bajorunas D, Jeziorska M, et al. · Investigative ophthalmology & visual science · 2017 · PMID 28475703

    Sarcoidosis frequently is complicated by small nerve fiber loss (SNFL), which can be quantified using corneal confocal microscopy (CCM). Prior studies suggest that the innate repair receptor agonist cibinetide reverses corneal nerve loss. This phase 2b, 28-day, randomized trial of 64 subjects with sarcoid-associated SNFL and neuropathic pain assessed the effect of cibinetide on corneal nerve fiber area (CNFA) and regenerating intraepidermal fibers (GAP-43+) as surrogate endpoints for disease mod…

  2. 3.

    Heij L, Niesters M, Swartjes M, Hoitsma E, et al. · Molecular medicine (Cambridge, Mass.) · 2012 · PMID 23168581

    ARA 290 (a peptide designed to activate the innate repair receptor that arrests injury and initiates cytoprotection, antiinflammation and healing) reduces allodynia in preclinical neuropathy models. We studied the safety and efficacy of ARA 290 to reduce symptoms of small fiber neuropathy (SFN) in patients with sarcoidosis. A total of 22 patients diagnosed with sarcoidosis and symptoms of SFN were enrolled in a double-blind, placebo-controlled exploratory trial consisting of three times weekly i…

  3. 4.

    Dahan A, Dunne A, Swartjes M, Proto PL, et al. · Molecular medicine (Cambridge, Mass.) · 2013 · PMID 24136731

    Small nerve fiber loss and damage (SNFLD) is a frequent complication of sarcoidosis that is associated with autonomic dysfunction and sensory abnormalities, including pain syndromes that severely degrade the quality of life. SNFLD is hypothesized to arise from the effects of immune dysregulation, an essential feature of sarcoidosis, on the peripheral and central nervous systems. Current therapy of sarcoidosis-associated SNFLD consists primarily of immune suppression and symptomatic treatment; ho…

Clinical Trials

1
  1. 5.

    Brines M, Dunne AN, van Velzen M, Proto PL, et al. · Molecular medicine (Cambridge, Mass.) · 2015 · PMID 25387363

    Although erythropoietin ameliorates experimental type 2 diabetes with neuropathy, serious side effects limit its potential clinical use. ARA 290, a nonhematopoietic peptide designed from the structure of erythropoietin, interacts selectively with the innate repair receptor that mediates tissue protection. ARA 290 has shown efficacy in preclinical and clinical studies of metabolic control and neuropathy. To evaluate the potential activity of ARA 290 in type 2 diabetes and painful neuropathy, subj…

Trial Registrations (ClinicalTrials.gov)

4
  1. 6.

    NCT01933529 · Phase 2 · Unknown · 2013

    Conditions: Diabetes Type 2, Impaired Glucose Tolerance, Impaired Fasting Glucose

  2. 7.

    NCT02070783 · Phase 1/Phase 2 · Completed · 2012

    Conditions: Depression

  3. 8.

    NCT06626971 · Phase 2 · Terminated · 2016

    Conditions: Diabetic Macular Oedema

  4. 9.

    NCT02039687 · Phase 2 · Completed · 2014

    Conditions: Neuropathy of Sarcoidosis

Reviews

4
  1. 10.

    van Velzen M, Heij L, Niesters M, Cerami A, et al. · Expert opinion on investigational drugs · 2014 · PMID 24555851

    Painful peripheral neuropathy is a common, difficult-to-treat complication associated with a variety of diseases, including diabetes mellitus and sarcoidosis. It is caused by damage of small and autonomic nerve fibers, resulting in potentially debilitating symptoms of neuropathic pain and autonomic dysfunction. The limited efficacy of current treatment options dictates a rationalized design of novel compounds. The authors present the recent data from two Phase II clinical trials on ARA290, an er…

  2. 11.

    Collino M, Thiemermann C, Cerami A, Brines M · Pharmacology & therapeutics · 2015 · PMID 25728128

    Many disease processes activate a cellular stress response that initiates a cascade of inflammation and damage. However, this process also triggers a tissue protection and repair system mediated by locally-produced hyposialated erythropoietin (hsEPO). Although recombinant EPO is used widely for treating anemia, potential use of recombinant EPO for tissue-protection is limited by rises in hematocrit, platelet activation, and selectin expression resulting in a high risk of thrombosis. Importantly,…

  3. 12.

    Sun Y, Song B, Zhang Y, Zhang Y, et al. · Frontiers in neurology · 2025 · PMID 41659975

    Traumatic brain injury (TBI) unfolds through a well-defined chronology-hyperacute excitotoxic and inflammasome bursts, acute apoptotic and blood-brain-barrier failure, and subacute neurovascular remodeling-that no single-pathway drug can adequately cover. Recombinant erythropoietin (EPO) limits secondary damage in animals, yet its erythropoietic drive and thrombotic liability have stalled clinical adoption. This review integrates structural biology, pharmacology and translational data on four en…

  4. 13.

    Liu G, Liang J, Li W, Jiang S, et al. · International immunopharmacology · 2024 · PMID 38943972

    Peripheral nerve injury seriously endangers human life and health, but there is no clinical drug for the treatment of peripheral nerve injury, so it is imperative to develop drugs to promote the repair of peripheral nerve injury. Erythropoietin (EPO) not only has the traditional role of promoting erythropoiesis, but also has a tissue-protective effect. Over the past few decades, researchers have confirmed that EPO has neuroprotective effects. However, side effects caused by long-term use of EPO…

Research Articles

55
  1. 14.

    Liu Y, Luo B, Shi R, Wang J, et al. · Scientific reports · 2015 · PMID 26459940

    Erythropoietin (EPO) has been identified as being crucial for obesity modulation; however, its erythropoietic activity may limit its clinical application. EPO-derived Helix B-surface peptide (pHBSP) is nonerythrogenic but has been reported to retain other functions of EPO. The current study aimed to evaluate the effects and potential mechanisms of pHBSP in obesity modulation. We found that pHBSP suppressed adipogenesis, adipokine expression and peroxisome proliferator-activated receptor γ (PPARγ…

  2. 15.

    Robertson CS, Garcia R, Gaddam SS, Grill RJ, et al. · Journal of neurotrauma · 2013 · PMID 22827443

    Mild traumatic brain injury (mTBI) results in an estimated 75-90% of the 1.7 million TBI-related emergency room visits each year. Post-concussion symptoms, which can include impaired memory problems, may persist for prolonged periods of time in a fraction of these cases. The purpose of this study was to determine if an erythropoietin-mimetic peptide, pyroglutamate helix B surface peptide (pHBSP), would improve neurological outcomes following mTBI. Sixty-four rats were randomly assigned to pHBSP…

  3. 16.

    McVicar CM, Hamilton R, Colhoun LM, Gardiner TA, et al. · Diabetes · 2011 · PMID 21911748

    Erythropoietin (EPO) may be protective for early stage diabetic retinopathy, although there are concerns that it could exacerbate retinal angiogenesis and thrombosis. A peptide based on the EPO helix-B domain (helix B-surface peptide [pHBSP]) is nonerythrogenic but retains tissue-protective properties, and this study evaluates its therapeutic potential in diabetic retinopathy. After 6 months of streptozotocin-induced diabetes, rats (n = 12) and age-matched nondiabetic controls (n = 12) were even…

  4. 17.

    Liu Y, Lu J, Wang X, Chen L, et al. · Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology · 2017 · PMID 28419985

    Traumatic brain injury (TBI) can be complicated by TBI-triggered acute lung injury (ALI), in which inflammation plays a central role. It has been reported that an Erythropoietin-derived peptide (pHBSP) was able to ameliorate TBI; however, its function in TBI-caused ALI has not been reported yet. In this study, we studied the effect of pHBSP on TBI-caused ALI by using a weight-drop induced TBI model. At 8 h and 24 h post-TBI, pulmonary edema (PE) and bronchoalveolar lavage fluid (BALF) proteins w…

  5. 18.

    Etscheid M, Beer N, Fink E, Seitz R, et al. · Biological chemistry · 2002 · PMID 12452440

    The influence of the hyaluronan-binding protease (PHBSP), a plasma enzyme with FVII- and pro-urokinase-activating potency, on components of the contact phase (kallikrein/kinin) system was investigated. No activation or cleavage of the proenzymes involved in the contact phase system was observed. The pro-cofactor high molecular weight kininogen (HK), however, was cleaved in vitro by PHBSP in the absence of any charged surface, releasing the activated cofactor and the vasoactive nonapeptide bradyk…

  6. 19.

    Collino M, Benetti E, Rogazzo M, Chiazza F, et al. · British journal of pharmacology · 2014 · PMID 25164531

    The haematopoietic activity of erythropoietin (EPO) is mediated by the classic EPO receptor (EpoR) homodimer, whereas tissue-protective effects are mediated by a heterocomplex between EpoR and the β-common receptor (βcR). Here, we investigated the effects of a novel, selective ligand of this heterocomplex - pyroglutamate helix B surface peptide (pHBSP) - in mice fed a diet enriched in sugars and saturated fats. Male C57BL/6J mice were fed a high-fat high-sucrose diet (HFHS) for 22 weeks. pHBSP (…

  7. 20.

    Nairz M, Haschka D, Dichtl S, Sonnweber T, et al. · Scientific reports · 2017 · PMID 29026145

    Two distinct forms of the erythropoietin receptor (EPOR) mediate the cellular responses to erythropoietin (EPO) in different tissues. EPOR homodimers signal to promote the maturation of erythroid progenitor cells. In other cell types, including immune cells, EPOR and the ß-common receptor (CD131) form heteromers (the innate repair receptor; IRR), and exert tissue protective effects. We used dextran sulphate sodium (DSS) to induce colitis in C57BL/6 N mice. Once colitis was established, mice were…

  8. 21.

    Netrebenko AS, Gureev VV, Pokrovskii MV, Gureeva AV, et al. · Archives of Razi Institute · 2021 · PMID 35096335

    Chronic kidney disease (CKD) or acute kidney injury (AKI) causes impaired kidney function, leading to cognitive impairment, neuropathy, and cerebrovascular disease. Due to kidney damage, toxins stay in the blood rather than leaving the body through the urine, and brain function is affected by kidney-brain interaction. The present study aimed to investigate the protective effects of erythropoietin mimetic peptide (pHBSP) and infliximab on ischemic renal reperfusion injury. The experiment was perf…

  9. 22.

    Yao M, Domogatskaya A, Ågren N, Watanabe M, et al. · Cell transplantation · 2021 · PMID 34498509

    During intra-portal pancreatic islet transplantation (PITx), innate immune reactions such as the instant blood mediated inflammatory reaction (IBMIR) cause an immediate loss of islets. The non-hematopoietic erythropoietin analogue cibinetide has previously shown islet-protective effects in mouse PITx. Herein, we aimed to confirm cibinetide's efficacy on human islets, and to characterize its effect on IBMIR. We cultured human islets with pro-inflammatory cytokines for 18 hours with or without cib…

  10. 23.

    Patel NS, Nandra KK, Brines M, Collino M, et al. · Molecular medicine (Cambridge, Mass.) · 2011 · PMID 21607291

    Recent studies have shown that erythropoietin, critical for the differentiation and survival of erythrocytes, has cytoprotective effects in a wide variety of tissues, including the kidney and lung. However, erythropoietin has been shown to have a serious side effect-an increase in thrombovascular effects. We investigated whether pyroglutamate helix B-surface peptide (pHBSP), a nonerythropoietic tissue-protective peptide mimicking the 3D structure of erythropoietin, protects against the organ inj…

  11. 24.

    Dennhardt S, Pirschel W, Wissuwa B, Imhof D, et al. · Frontiers in immunology · 2022 · PMID 36211426

    Hemolytic-uremic syndrome (HUS) can occur as a systemic complication of infections with Shiga toxin (Stx)-producing

  12. 25.

    Etscheid M, Hunfeld A, König H, Seitz R, et al. · Biological chemistry · 2000 · PMID 11209757

    The hyaluronic acid binding serine protease (PHBSP), an enzyme with the ability to activate the coagulation factor FVII and the plasminogen activator precursors and to inactivate factor VIII and factor V, could be isolated from human plasma in the presence of 6M urea as a single-chain zymogen, whereas under native conditions only its activated two-chain form was obtained. The total yield of proenzyme (proPHBSP) was 5-6 mg/l, corresponding to a concentration of at least 80-100nM in plasma. Upon r…

  13. 26.

    Liu G, Li W, Jiang S, Liang J, et al. · European journal of pharmacology · 2025 · PMID 40216181

    The challenge of repairing peripheral nerve injury is a critical issue that needs to be addressed urgently. Previous research has shown that erythropoietin (EPO) and its prolonged peptides exhibit beneficial effects in neurological disorders. In our study, we demonstrated that both EPO and pyroglutamic acid helix B surface peptide (pHBSP, also known as ARA290) inhibit the early inflammatory response and promote functional recovery after sciatic nerve crush injury in rat models. Our experimental…

  14. 27.

    Robertson CS, Cherian L, Shah M, Garcia R, et al. · Journal of neurotrauma · 2012 · PMID 21545288

    Pyroglutamate helix B surface peptide (pHBSP) is an 11 amino acid peptide, designed to interact with a novel cell surface receptor, composed of the classical erythropoietin (EPO) receptor disulfide linked to the beta common receptor. pHBSP has the cytoprotective effects of EPO without stimulating erythropoiesis. Effects on early cerebral hemodynamics and neurological outcome at 2 weeks post-injury were compared in a rat model of mild cortical impact injury (3m/sec, 2.5 mm deformation) followed b…

  15. 28.

    Yao M, Watanabe M, Sun S, Tokodai K, et al. · Transplantation · 2020 · PMID 32345869

    During intraportal pancreatic islet transplantation (PITx), early inflammatory reactions cause an immediate loss of more than half of the transplanted graft and potentiate subsequent allograft rejection. Previous findings suggest that cibinetide, a selective innate repair receptor agonist, exerts islet protective and antiinflammatory properties and improved transplant efficacy in syngeneic mouse PITx model. In a stepwise approach toward a clinical application, we have here investigated the short…

  16. 29.

    Lois N, Gardner E, McFarland M, Armstrong D, et al. · Journal of clinical medicine · 2020 · PMID 32674280

    Evaluating the effects of cibinetide in diabetic macular edema (DME). Phase 2 trial. Naïve patients with >400 µm central retinal thickness (CRT) DME in one/both eyes were recruited (May 2016-April 2017) at the Belfast Health and Social Care Trust. The study eye was that with best vision and lowest CRT. Patients self-administered cibinetide 4 mg/day subcutaneously for 12 weeks. Primary and secondary outcomes: mean change from baseline to week 12 in best corrected visual acuity (BCVA), CRT, centra…

  17. 30.

    Mohtavinejad N, Amanlou M, Bitarafan-Rajabi A, Khalaj A, et al. · Bioorganic chemistry · 2020 · PMID 32171100

    In cardiac ischemic disorder, pyroglutamate helix B surface peptide (pHBSP) which derived from erythropoietin causes to increase cell stability. To improve the serum stability of pHBSP, two lipophilic amino acids Arg

  18. 31.

    Al-Onaizi MA, Thériault P, Lecordier S, Prefontaine P, et al. · Brain, behavior, and immunity · 2022 · PMID 34343617

    Alzheimer's disease (AD) pathology is characterized by amyloid-β (Aβ) deposition and tau hyper-phosphorylation, accompanied by a progressive cognitive decline. Monocytes have been recently shown to play a major role in modulating Aβ pathology, and thereby have been pointed as potential therapeutic targets. However, the main challenge remains in identifying clinically relevant interventions that could modulate monocyte immune functions in absence of undesired off-target effects. Erythropoietin (E…

  19. 32.

    Patel NS, Kerr-Peterson HL, Brines M, Collino M, et al. · Molecular medicine (Cambridge, Mass.) · 2012 · PMID 22415011

    In preclinical studies, erythropoietin (EPO) reduces ischemia-reperfusion-associated tissue injury (for example, stroke, myocardial infarction, acute kidney injury, hemorrhagic shock and liver ischemia). It has been proposed that the erythropoietic effects of EPO are mediated by the classic EPO receptor homodimer, whereas the tissue-protective effects are mediated by a hetero-complex between the EPO receptor monomer and the β-common receptor (termed "tissue-protective receptor"). Here, we invest…

  20. 33.

    Zhang W, Yu G, Zhang M · Peptides · 2016 · PMID 26774587

    ARA 290 is an erythropoietin-derived polypeptide that possesses analgesic and tissue protective effect in many diseases such as diabetes and cancer. The analgesic effect of ARA 290 is mediated by its anti-inflammatory and immunomodulatory functions, or more specifically, by targeting the innate repair receptor (IRR) to down-regulate inflammation to alleviate neuropathic pain. However, whether other mechanisms or pathways are involved in ARA 290-mediated analgesic effect remains elusive. In this…

  21. 34.

    Bitto A, Irrera N, Pizzino G, Pallio G, et al. · Biochimica et biophysica acta. Molecular basis of disease · 2018 · PMID 29223734

    Diabetes is characterized by poor wound healing which currently lacks an efficacious treatment. The innate repair receptor (IRR) is a master regulator of tissue protection and repair which is expressed as a response injury or metabolic stress, including in diabetes. Activation of the IRR might provide benefit for diabetic wound healing. A specific IRR agonist cibinetide was administered in an incisional wound healing model performed mice with genetic diabetes (db

  22. 35.

    Brines M, Culver DA, Ferdousi M, Tannemaat MR, et al. · Scientific reports · 2018 · PMID 29549285

    Small fiber neuropathy (SFN) is a common feature of many inflammatory diseases, often presenting with pain and disability. SFN is diagnosed using symptoms, thermal threshold testing, and intra-epidermal nerve fiber quantification. Corneal confocal microscopy (CCM) is an ophthalmic imaging technique which non-invasively quantifies corneal nerve fiber (CNF) density, branch density and length, and has comparable diagnostic and superior ability to identify nerve regeneration compared to skin biopsy.…

  23. 36.

    Seeger N, Zellinger C, Rode A, Roloff F, et al. · Epilepsia · 2011 · PMID 22050420

    The selection of a minimal active sequence of erythropoietin allowed the design of peptide mimetics that exert beneficial effects in the central nervous system but lack an erythropoietic effect. Erythropoietin has been suggested as a promising therapeutic and prophylactic for epilepsies based on its neuroprotective, neuroregenerative, and antiinflammatory potency. Therefore, it is of particular interest to evaluate whether the nonerythropoietic erythropoietin-derived peptide pHBSP can affect epi…

  24. 37.

    Watanabe M, Lundgren T, Saito Y, Cerami A, et al. · Transplantation · 2016 · PMID 26683514

    Erythropoietin exerts anti-inflammatory, antiapoptotic, and cytoprotective effects in addition to its hematopoietic action. A nonhematopoietic erythropoietin analogue, ARA 290, has similar properties. The efficacy of pancreatic islet transplantation (PITx) is reduced due to islet damage that occurs during isolation and from the severe inflammatory reactions caused by the transplantation procedure. We investigated whether ARA 290 protects islets and ameliorates inflammatory responses following PI…

  25. 38.

    Winicki NM, Nanavati AP, Morrell CH, Moen JM, et al. · Frontiers in cardiovascular medicine · 2022 · PMID 36741836

    Aging is associated with increased levels of reactive oxygen species and inflammation that disrupt proteostasis and mitochondrial function and leads to organism-wide frailty later in life. ARA290 (cibinetide), an 11-aa non-hematopoietic peptide sequence within the cardioprotective domain of erythropoietin, mediates tissue protection by reducing inflammation and fibrosis. Age-associated cardiac inflammation is linked to structural and functional changes in the heart, including mitochondrial dysfu…

  26. 39.

    Hunfeld A, Etscheid M, König H, Seitz R, et al. · FEBS letters · 1999 · PMID 10456326

    A novel serine protease (PHBSP) was purified from human plasma by two chromatographic steps with a final yield of 1.6 mg/l plasma. The protease consists of two disulfide-bridged chains of about 50 and 30 kDa with the light chain containing the active site of the enzyme. NH2-terminal sequence analysis revealed identity to the deduced amino acid sequence of HGFA-like mRNA. The activity of PHBSP is strongly dependent on Ca2+ ions and is efficiently inhibited by alpha2-antiplasmin and aprotinin. Pos…

  27. 40.

    Awida Z, Bachar A, Saed H, Gorodov A, et al. · International journal of molecular sciences · 2021 · PMID 35008482

    The two erythropoietin (EPO) receptor forms mediate different cellular responses to erythropoietin. While hematopoiesis is mediated via the homodimeric EPO receptor (EPOR), tissue protection is conferred via a heteromer composed of EPOR and CD131. In the skeletal system, EPO stimulates osteoclast precursors and induces bone loss. However, the underlying molecular mechanisms are still elusive. Here, we evaluated the role of the heteromeric complex in bone metabolism in vivo and in vitro by using…

  28. 41.

    Mohtavinejad N, Hajiramezanali M, Akhlaghi M, Bitarafan-Rajabi A, et al. · Iranian journal of basic medical sciences · 2021 · PMID 35317117

    Myocardial infarction caused by ischemia of heart tissue is the main reason for death worldwide; therefore, early detection can reduce mortality and treatment costs. Erythropoietin (EPO) has protection effects on ischemic tissue due to nonhematopoietic peptide (pHBSP; ARA-290) which is derived from the B-subunit of EPO. We designed and synthesized a modified DOTA-(Lys-Dabcyl Radiolabeling purity was obtained more than 96% by ITLC, and in vitro stability of the radiopeptide up to 6 hr was 85%. Th…

  29. 42.

    Liu Y, Luo B, Han F, Li X, et al. · PloS one · 2014 · PMID 24603865

    Experimental autoimmune neuritis (EAN) is an autoantigen-specific T-cell-mediated disease model for human demyelinating inflammatory disease of the peripheral nervous system. Erythropoietin (EPO) has been known to promote EAN recovery but its haematopoiesis stimulating effects may limit its clinic application. Here we investigated the effects and potential mechanisms of an EPO-derived nonerythropoietic peptide, ARA 290, in EAN. Exogenous ARA 290 intervention greatly improved EAN recovery, improv…

  30. 43.

    Heikal L, Ghezzi P, Mengozzi M, Stelmaszczuk B, et al. · Hypoxia (Auckland, N.Z.) · 2016 · PMID 27800514

    The cytoprotective effects of erythropoietin (EPO) and an EPO-related nonerythropoietic analog, pyroglutamate helix B surface peptide (pHBSP), were investigated in an in vitro model of bovine aortic endothelial cell injury under normoxic (21% O

  31. 44.

    O'Leary OE, Canning P, Reid E, Bertelli PM, et al. · Experimental eye research · 2019 · PMID 30876881

    Retinal ischemia remains a common sight threatening end-point in blinding diseases such as diabetic retinopathy and retinopathy of prematurity. Endothelial colony forming cells (ECFCs) represent a subpopulation of endothelial progenitors with therapeutic utility for promoting reparative angiogenesis in the ischaemic retina. The current study has investigated the potential of enhancing this cell therapy approach by the dampening of the pro-inflammatory milieu typical of ischemic retina. Based on…

  32. 45.

    Heikal L, Ghezzi P, Mengozzi M, Ferns G · Molecular medicine (Cambridge, Mass.) · 2015 · PMID 26349058

    Erythropoietin (EPO) has both erythropoietic and tissue-protective properties. The EPO analogues carbamylated EPO (CEPO) and pyroglutamate helix B surface peptide (pHBSP) lack the erythropoietic activity of EPO but retain the tissue-protective properties that are mediated by a heterocomplex of EPO receptor (EPOR) and the β common receptor (βCR). We studied the action of EPO and its analogues in a model of wound healing where a bovine aortic endothelial cells (BAECs) monolayer was scratched and t…

  33. 46.

    Korokin M, Gureev V, Gudyrev O, Golubev I, et al. · International journal of molecular sciences · 2020 · PMID 32942669

    Preeclampsia is a severe disease of late pregnancy. Etiological factors and a pathogenetic pattern of events still require significant clarification, but it is now recognized that a large role is played by placentation disorders and emerging endothelial dysfunction. The administration of short-chain peptides mimicking the spatial structure of the B erythropoietin chain may become one of the directions of searching for new drugs for preeclampsia prevention and therapy. Simulation of ADMA-like pre…

  34. 47.

    Joshi D, Abraham D, Shiwen X, Baker D, et al. · Journal of vascular surgery · 2014 · PMID 24055514

    Managing critical limb ischemia (CLI) is challenging. Furthermore, ischemic myopathy prevents good functional outcome after revascularization. Hence, we have focused on limiting the tissue damage rather than angiogenesis, which has traditionally been the motivation to develop nonsurgical treatments for CLI. Erythropoietin (EPO) protects ischemic tissue, and this property may also benefit CLI. The objective of this study was to examine the expression of the tissue-protective EPO receptor complex…

  35. 48.

    Swartjes M, van Velzen M, Niesters M, Aarts L, et al. · Molecular pain · 2014 · PMID 24529189

    Neuropathic pain is a difficult to treat disorder arising from central or peripheral nervous system lesions. The etiology of neuropathic pain consists of several overlapping pathways converging into an exaggerated pain state with symptoms such as allodynia and hyperalgesia. One of these pathways involves activation of spinal cord microglia and astrocytes, which drive and maintain the inflammatory response following the lesion. These cells are a potential target for drugs for neuropathic pain rel…

  36. 49.

    Alasousi D, Braysh K, D'Souza L, Islam S, et al. · Neurobiology of disease · 2026 · PMID 41933665

    Type 2 diabetes (T2D) is associated with cognitive impairment, with executive functions such as cognitive flexibility being particularly vulnerable. Growing evidence suggests that chronic inflammatory and metabolic stress contributes to diabetes -related brain dysfunction, yet behavioral assessment in animal models is often confounded by anxiety, altered motivation, and reduced response vigor. In this study, we used a translational touchscreen-based operant platform to distinguish associative le…

  37. 50.

    Swartjes M, Niesters M, Heij L, Dunne A, et al. · PloS one · 2013 · PMID 23936499

    Neuropathic pain (NP) is a debilitating condition associated with traumatic, metabolic, autoimmune and neurological etiologies. Although the triggers for NP are diverse, there are common underlying pathways, including activation of immune cells in the spinal cord and up-regulation of the N-methyl-D-aspartate receptor (NMDAR). Ketamine, a well-known NDMAR antagonist, reduces neuropathic pain in a sustained manner. Recent study has shown that the novel 11-amino acid peptide erythropoietin derivati…

  38. 51.

    Thomas A, Knoop A, Schänzer W, Thevis M · Drug testing and analysis · 2017 · PMID 28941172

    With an increasing number of prohibited substances in doping controls, knowledge about their metabolism is crucial for efficient analysis. While for low molecular mass molecules, standard protocols for in vitro metabolism experiments are well established, the situation with peptidic drugs has been shown to be substantially more heterogeneous and complex. Two principle strategies aiming at simulating the metabolism of lower molecular mass peptides in vitro are presented within this study. The pro…

  39. 52.

    Patel NSA, Kerr-Peterson HL, Brines M, Collino M, et al. · Molecular medicine (Cambridge, Mass.) · 2026 · PMID 41749083

  40. 53.

    Shokrzadeh M, Etebari M, Ghassemi-Barghi N · Toxicology in vitro : an international journal published in association with BIBRA · 2020 · PMID 32335150

    Erythropoietin (EPO) applies anti-inflammatory, anti-apoptotic, anti-oxidant and cytoprotective effects besides its hematopoietic action. A nonhematopoietic peptide engineered from EPO, ARA 290, interacts selectively with the innate repair receptor and has similar possessions. ARA290 mediates tissue protection without hematopoietic side-effects of EPO which limit its clinical application. Doxorubicin (DOX) is the broad-spectrum chemotherapeutic agent, but its use is limited by the development of…

  41. 54.

    Ghassemi-Barghi N, Ehsanfar Z, Mohammadrezakhani O, Ashari S, et al. · Inflammation · 2023 · PMID 36085231

    ARA 290, an 11-amino acid linear nonhematopoietic peptide derived from the three-dimensional structure of helix B of the erythropoietin (EPO), interacts selectively with the innate repair receptor (IRR) that arbitrates tissue protection. The aim of this study was to investigate the protective effects of ARA290 against cisplatin-induced nephrotoxicity. For this purpose, HEK-293 and ACHN cells were treated with ARA290 (50-400 nM) and cisplatin (2.5 μM) in pretreatment condition. Then, cytotoxicity…

  42. 55.

    Sanchis-Gomar F, Perez-Quilis C, Lippi G · Molecular medicine (Cambridge, Mass.) · 2013 · PMID 23615965

    The erythropoietin receptor (EpoR) was discovered and described in red blood cells (RBCs), stimulating its proliferation and survival. The target in humans for EpoR agonists drugs appears clear-to treat anemia. However, there is evidence of the pleitropic actions of erythropoietin (Epo). For that reason, rhEpo therapy was suggested as a reliable approach for treating a broad range of pathologies, including heart and cardiovascular diseases, neurodegenerative disorders (Parkinson's and Alzheimer'…

  43. 56.

    Bratchikov O I, Kondrashov M M, Kostina D A, Shcheblykina O V · Urologiia (Moscow, Russia : 1999) · 2023 · PMID 38156685

    To study the efficiency of pre-administration of a peptide mimicking the spatial structure of erythropoietin -chain B in modeling experimental post-contrast acute kidney injury. In this study, an experimental model of post-contrast acute kidney injury was created using a non-steroidal anti-inflammatory drug, a nitric oxide synthase inhibitor, and injection of iopromide to mature male mice. After 48 hours, a comprehensive assessment of the concentration of creatinine, urea, glomerular filtration…

  44. 57.

    Patel N, Kerr-Peterson H, Brines M, Collino M, Rogazzo M, Fantozzi R, Wood E, Johnson F, Yaqoob M, Cerami A, Thiemermann C. · 2026

  45. 58.

    Relja B, Coldewey SM, Ghezzi P, Martin L, Thiemermann C. · 2023 · PMID 37304276

  46. 59.

    Yang Z, Wang R, Zheng Y, Luo Y. · 2023 · PMID 37008064

    Erythropoietin is generally assumed to have protective effects against multiple diseases, especially ischemic stroke, and myocardial infarctions. The theory behind Erythropoietin's (EPO) protective effects has been misconstrued in the scientific community to a degree, with assumptions made that the β common receptor (βcR) in the heteroreceptor EPO receptor (EPOR)/βcR is responsible for these protective effects. Our purpose with this opinion article is to convey our concern for the general assump…

  47. 60.

    Peng B, Kong G, Yang C, Ming Y. · 2020 · PMID 32015330

    Erythropoietin (EPO) is an evolutionarily conserved hormone well documented for its erythropoietic role via binding the homodimeric EPO receptor (EPOR)<sub>2</sub>. In past decades, evidence has proved that EPO acts far beyond erythropoiesis. By binding the tissue-protective receptor (TPR), EPO suppresses proinflammatory cytokines, protects cells from apoptosis and promotes wound healing. Very recently, new data revealed that TPR is widely expressed on a variety of immune cells, and EPO could di…

  48. 61.

    Zhao LJ, Sun XL, Qiu J, Xiao BL, Fan XY, Wang T, Li CL. · 2021 · PMID 34134477

  49. 62.

    Huang B, Jiang J, Luo B, Zhu W, Liu Y, Wang Z, Zhang Z. · 2018 · PMID 29570934

    Systemic lupus erythematosus (SLE) is an autoimmune disease, which results in various organ pathologies. However, current treatment towards SLE is suboptimal. Erythropoietin (EPO) has been shown to promote SLE recovery, but clinical application can be limited by its haematopoiesis-stimulating effects. EPO-derived helix-B peptide (ARA290) is non-erythrogenic but has been reported to retain the anti-inflammatory and tissue-protective functions of EPO. Therefore, here we investigated the effects an…

  50. 63.

    Tracey KJ. · 2013 · PMID 24178588

  51. 64.

    Joshi D, Tsui J, Yu R, Shiwen X, Selvakumar S, Abraham DJ, Baker DM. · 2012 · PMID 22462027

    Erythropoietin (EPO) has tissue-protective properties, but it increases the risk of thromboembolism by raising the haemoglobin concentration. New generation of EPO derivatives is tissue protective without the haematopoietic side effects. Preclinical studies have demonstrated their effectiveness and safety. This paper summarizes the development in EPO derivatives with emphasis on their potential use in critical limb ischaemia.

  52. 65.

    Wang RL, Yang ZH, Huang YY, Hu Y, Wang YL, Yan F, Zheng YM, Han ZP, Fan JF, Tao Z, Zhao HP, Li SJ, Luo YM. · 2024 · PMID 38488446

    <h4>Aim</h4>To explore the neuroprotective effects of ARA290 and the role of β-common receptor (βCR) in a mouse model of middle cerebral artery occlusion (MCAO).<h4>Methods</h4>This study included male C57BL/6J mice that underwent MCAO and reperfusion. The neuroprotective effect of ARA290 on MCAO-induced brain injury was investigated using neurological function tests (Longa and modified neurological severity score). Cerebral infarction was examined by 2, 3, 5-triphenyl tetrazolium chloride stain…

  53. 66.

    Newton SS, Sathyanesan M. · 2021 · PMID 34552490

    Cognitive deficits are widespread in psychiatric disorders, including major depression and schizophrenia. These deficits are known to contribute significantly to the accompanying functional impairment. Progress in the development of targeted treatments of cognitive deficits has been limited and there exists a major unmet need to develop more efficacious treatments. Erythropoietin (Epo) has shown promising procognitive effects in psychiatric disorders, providing support for a neurotrophic drug de…

  54. 67.

    Wang Y, Tang Y, Wang M, Li W, Mu W, Seyam A, Dai Y, Hou T, Guan X. · 2025 · PMID 40680515

    <h4>Introduction and aims</h4>Existing research suggests that ARA290 may possess therapeutic potential for apical periodontitis (AP), although the mechanisms involved remain unclear. This study aims to investigate the protective effects and underlying mechanisms of ARA290 in mitigating pro-inflammatory responses of macrophages in the context of AP.<h4>Methods</h4>Initially, in vivo models of AP were used to assess the aberrant activation of the SIRT1/NF-κB/IL-1β signalling pathway within periapi…

  55. 68.

    Patel NS, Nandra KK, Thiemermann C. · 2012 · PMID 22839413

    Erythropoietin (EPO) is known to have numerous biological functions. Its primary function in the body is to increase red blood cell numbers by way of preventing the apoptosis of erythroid progenitor cells via the homodimeric EPO receptor. The discovery that the local production of EPO within the brain in response to hypoxia or ischemia protects neurons against injury via an anti-apoptotic effect formed the basis of the hypothesis that the local generation of EPO limits the extent of injury. Alth…

Curated sources on file

3
  1. 1.
  2. 2.
  3. 3.

Continue reading